CanSino Biologics Inc.
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 2009-01-13
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.cansinotech.com
- Introduction
The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.
Clinical Trials
35
Trial Phases
6 Phases
Drug Approvals
5
Drug Approvals
Recombinant Ebola Virus Disease Vaccine (Adenovirus Type 5 Vector)
- Product Name
- 重组埃博拉病毒病疫苗(腺病毒载体)
- Approval Number
- 国药准字S20170008
- Approval Date
- Oct 13, 2022
Recombinant COVID-19 Vaccine （Adenovirus Type 5 Vector）
- Product Name
- 克威莎
- Approval Number
- 国药准字S20210004
- Approval Date
- Feb 23, 2022
Recombinant COVID-19 Vaccine（Adenovirus Type 5 Vector）
- Product Name
- 克威莎
- Approval Number
- 国药准字S20217005
- Approval Date
- Feb 23, 2022
Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)
- Product Name
- 曼海欣
- Approval Number
- 国药准字S20210054
- Approval Date
- Dec 27, 2021
Group A and Group C Meningococcal Conjugate Vaccine（CRM197）
- Product Name
- 美奈喜/Menphecia
- Approval Number
- 国药准字S20210018
- Approval Date
- Jun 22, 2021
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
- Conditions
- Pneumococcal InfectionsStreptococcal InfectionsBacterial Infections
- Interventions
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT07017777
Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis
- Interventions
- Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 780
- Registration Number
- NCT06857370
- Locations
- 🇨🇳
Changge Center for Disease Control and Prevention, Xuchang, Henan, China
A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06732583
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- Conditions
- DiphtheriaTetanusPertussis
- Interventions
- Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))Biological: 23-valent Pneumococcal Polysaccharide Vaccine (PPV23)Biological: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 1820
- Registration Number
- NCT06708286
- Locations
- 🇨🇳
Kaihua County Center for Disease Control and Prevention, Kaihua, China
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
- Conditions
- Meningococcal Meningitis
- Interventions
- Biological: MPSV4
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 840
- Registration Number
- NCT06700148
- Locations
- 🇨🇳
Dengfeng Center for Disease Control and Prevention, Dengfeng, China
🇨🇳Kaifeng Center for Disease Control and Prevention, Kaifeng, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
CanSino Biologics Initiates Phase I/II Trial of Recombinant Polio Vaccine in Indonesia
CanSino Biologics has commenced a Phase I/II clinical trial in Indonesia for its Recombinant Poliomyelitis Vaccine (CS-2036).